First Time Loading...

Cerevel Therapeutics Holdings Inc
NASDAQ:CERE

Watchlist Manager
Cerevel Therapeutics Holdings Inc Logo
Cerevel Therapeutics Holdings Inc
NASDAQ:CERE
Watchlist
Price: 40.27 USD 0.62% Market Closed
Updated: Jun 11, 2024

Cerevel Therapeutics Holdings Inc
Stock-Based Compensation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cerevel Therapeutics Holdings Inc
Stock-Based Compensation Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Stock-Based Compensation Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Cerevel Therapeutics Holdings Inc
NASDAQ:CERE
Stock-Based Compensation
$69.4m
CAGR 3-Years
88%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Stock-Based Compensation
$782m
CAGR 3-Years
-1%
CAGR 5-Years
13%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Stock-Based Compensation
$788m
CAGR 3-Years
7%
CAGR 5-Years
1%
CAGR 10-Years
11%
Amgen Inc
NASDAQ:AMGN
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Stock-Based Compensation
$650.7m
CAGR 3-Years
15%
CAGR 5-Years
14%
CAGR 10-Years
16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Cerevel Therapeutics Holdings Inc's Stock-Based Compensation?
Stock-Based Compensation
69.4m USD

Based on the financial report for Dec 31, 2023, Cerevel Therapeutics Holdings Inc's Stock-Based Compensation amounts to 69.4m USD.

What is Cerevel Therapeutics Holdings Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 3Y
88%

Over the last year, the Stock-Based Compensation growth was 79%. The average annual Stock-Based Compensation growth rates for Cerevel Therapeutics Holdings Inc have been 88% over the past three years .